Form 4 Filing for Allogene Therapeutics, Inc. - Ownership Change

This filing details a Form 4 filed by Owen N. Witte, a director at Allogene Therapeutics, Inc. On June 18, 2026, Mr. Witte was awarded 95,400 Restricted Stock Units (RSUs) of the company's Common Stock. These RSUs vest in two equal semi-annual installments over one year, contingent upon continued service. Mr. Witte has elected to defer the receipt of the Common Stock until after separation from the company or a change in control, as per the Non-Employee Director Compensation Policy. The transaction is reported as a direct acquisition.